Enclomiphene Side Effects: What Studies Report

Enclomiphene citrate appears in the andrology literature as an orally administered estrogen receptor antagonist studied in men with testosterone deficiency. Interest in its safety profile comes largely from comparisons with clomiphene citrate and with exogenous testosterone. This page summarises what published trials, reviews, meta-analyses and case reports stated about tolerability and adverse events, and it flags the many endpoints those papers did not measure. This page is for educational purposes only and is not medical advice; consult a licensed physician about any medication, hormone or investigational compound.

What enclomiphene is in the published literature

A 2009 drug profile characterised enclomiphene as an estrogen receptor antagonist under investigation for testosterone deficiency in men, describing it as the trans-isomer separated from the clomiphene citrate isomer mixture (PMID 19204885). That separation is the pharmacological premise behind much of the safety discussion: the 2009 review discussed the rationale for isolating the antiestrogenic isomer rather than administering the mixed product (PMID 19204885).

A 2016 pharmacotherapy review examined enclomiphene citrate specifically for secondary male hypogonadism, covering its hormonal effects and its tolerability in that population (PMID 27337642). A 2019 review framed enclomiphene as a treatment intended to maintain fertility in men with secondary hypogonadism, in contrast to testosterone replacement (PMID 31063005). A 2024 review then compared the safety and efficacy of enclomiphene and clomiphene in hypogonadal men directly (PMID 39434750), and a 2025 systematic review and meta-analysis pooled randomized controlled trials of clomiphene or enclomiphene citrate for male hypogonadism (PMID 41066380).

Readers looking for mechanism, trial design and how hypothalamic–pituitary–gonadal feedback is measured will find that material in PeptideU's enclomiphene course; this page stays on safety reporting so the two do not repeat each other.

Reported Adverse Events Across Trials and Reviews: What Studies Report

The most important structural point about enclomiphene safety data is how it was generated. Adverse events in this field were collected inside comparatively short hormone-endpoint studies, and the 2025 systematic review and meta-analysis of randomized controlled trials was assembled from that same pool of trials in men with hypogonadism (PMID 41066380). Researchers in the 2024 comparison of enclomiphene and clomiphene treated safety as a distinct outcome of interest rather than an afterthought, which is why that paper is the usual starting point for tolerability questions (PMID 39434750).

Because enclomiphene and clomiphene are frequently discussed together, the two agents' adverse-event profiles are often conflated in secondary sources. The 2024 review addressed them as separate entities in hypogonadal men (PMID 39434750), and the isomer distinction described in 2009 is what makes that separation pharmacologically meaningful (PMID 19204885). Statements that begin "clomiphene causes X, therefore enclomiphene causes X" are inferences, not findings reported in these papers.

Why symptom lists vary between sources

Many popular side-effect lists trace back to trial safety tables that are not reproduced in the abstracts or titles of the papers cited here. This page therefore names only adverse events that the cited reports themselves stated. Where a specific symptom is not named below, that absence reflects the boundary of what these particular publications reported, not evidence that the symptom has never been recorded. The 2016 review remains the reference point for how tolerability was discussed in secondary hypogonadism (PMID 27337642).

A Cardiac Event Described in a Case Report: What Studies Report

The single most specific adverse event in the verified enclomiphene literature is a 2026 case report describing newly detected atrial flutter after enclomiphene dose escalation in a patient with prior mitral valve repair and chronic immune thrombocytopenia (PMID 42741668). Several features of that report matter for interpretation. It was a single patient; the individual had pre-existing structural cardiac surgery history and a chronic haematological condition; and the arrhythmia was noted following an increase in dose, as reported in the case description (PMID 42741668).

Case reports establish temporal association, not causation or incidence. Nothing in that publication quantified how often such an event occurs, and the pooled randomized trial evidence summarised in 2025 was not designed around cardiac rhythm endpoints (PMID 41066380). The report's value is as a signal that clinicians documented and published, and as a reminder that comorbidity context shaped that single case (PMID 42741668).

Fertility and Semen Outcomes: What Studies Report

A recurring theme is that enclomiphene was studied precisely because of a safety concern attached to another therapy. A 2019 review described enclomiphene citrate as a treatment that maintains fertility in men with secondary hypogonadism (PMID 31063005), and a 2025 review of innovations in replacement and stimulatory therapies framed the preservation of spermatogenesis during testosterone deficiency treatment as the central design problem (PMID 41522318). The 2016 pharmacotherapy review positioned enclomiphene within secondary hypogonadism management on the same grounds (PMID 27337642).

In other words, the fertility conversation in this literature is largely about an adverse effect of exogenous androgens that stimulatory approaches were investigated to avoid, as the 2025 review discussed (PMID 41522318). That does not mean semen parameters were unaffected by enclomiphene in every study; it means the published reviews treated fertility preservation as the comparative advantage being tested (PMID 31063005).

Hormonal changes described in the trial literature

Hormone outcomes are not adverse events, but they are the context in which adverse events were recorded. The table below summarises which cited report examined which outcome.

The 2026 retrospective case series examined changes in serum testosterone after sublingual enclomiphene citrate combined with a mineral oxide delivery system in 15 men (PMID 42170362). A retrospective series of that size, without a control group, cannot characterise adverse-event frequency, and the study was framed around a hormonal outcome (PMID 42170362).

Populations studied, and why that limits generalisation

Men with secondary hypogonadism

This is the population the core reviews addressed: the 2016 pharmacotherapy review and the 2019 fertility-focused review both centred on secondary male hypogonadism (PMID 27337642, PMID 31063005). Safety observations drawn from that group do not automatically transfer to men without a diagnosed deficiency, and none of the cited papers reported on healthy men using the compound outside a clinical indication.

Obesity-associated androgen deficiency

A 2023 systematic review and meta-analysis examined selective modulation of the estrogen receptor in obese men with androgen deficiency (PMID 36604313). Researchers in that analysis grouped selective estrogen receptor modulator data in a metabolically distinct population, which is relevant because obesity alters baseline estradiol and gonadotropin relationships (PMID 36604313).

Off-label use after anabolic steroid exposure

A 2026 review addressed clomiphene citrate in off-label post-cycle therapy, covering mechanisms, efficacy and the diagnostic challenges of assessing endocrine recovery after anabolic steroid use (PMID 42387872). That paper concerned clomiphene rather than enclomiphene, and the diagnostic difficulty it described — distinguishing drug effect from spontaneous recovery of the axis — is a methodological caution for anyone reading self-reported outcomes in this setting (PMID 42387872).

Formulation and regulatory context

Formulation is part of the safety picture because delivery route changes exposure. The 2026 case series used a sublingual enclomiphene citrate preparation combined with a mineral oxide delivery system, which is not the oral tablet form used in the earlier trial literature (PMID 42170362). Enclomiphene has been discussed in reviews as an investigational agent for testosterone deficiency rather than a long-established approved product (PMID 19204885), and product availability, labelling and compounding rules differ by country and change over time. Regulatory status is a factual matter to verify with current official sources.

Gaps the literature itself identifies

• Duration. The randomized evidence pooled in the 2025 meta-analysis came from trials in male hypogonadism rather than from multi-year safety studies (PMID 41066380).
• Hard outcomes. Cardiovascular, fracture and mortality endpoints were not the focus of the reviews comparing enclomiphene and clomiphene in hypogonadal men (PMID 39434750).
• Sample size. The 2026 series included only 15 men and was retrospective (PMID 42170362).
• Signal interpretation. The atrial flutter report involved one patient with prior mitral valve repair and chronic immune thrombocytopenia (PMID 42741668).
• Comparator drift. Reviews of stimulatory versus replacement therapy noted that the field continues to evolve, including interest in Leydig stem cell approaches for hypogonadism (PMID 33003069, PMID 41522318).

Taken together, the published record on enclomiphene tolerability is built from short hormone-endpoint trials, two systematic reviews, several narrative reviews, a small retrospective series and one detailed case report. Anyone weighing safety questions is reading a young evidence base, and the clinical relevance of any individual finding is a matter for a licensed physician who can assess the whole person.

References

• Safety and efficacy of enclomiphene and clomiphene for hypogonadal men (Translational Andrology and Urology, 2024)
• Enclomiphene, an estrogen receptor antagonist for the treatment of testosterone deficiency in men (IDrugs, 2009)
• Clomiphene or enclomiphene citrate for the treatment of male hypogonadism: a systematic review and meta-analysis of randomized controlled trials (Archives of Endocrinology and Metabolism, 2025)
• Enclomiphene citrate for the treatment of secondary male hypogonadism (Expert Opinion on Pharmacotherapy, 2016)
• Enclomiphene citrate: A treatment that maintains fertility in men with secondary hypogonadism (Expert Review of Endocrinology & Metabolism, 2019)
• Changes in Serum Testosterone After Sublingual Enclomiphene Citrate Combined With a Mineral Oxide Delivery System: A Retrospective Case Series of 15 Men (Cureus, 2026)
• Selective modulation of estrogen receptor in obese men with androgen deficiency: A systematic review and meta-analysis (Andrology, 2023)
• Preserving spermatogenesis in testosterone deficiency: innovations in replacement and stimulatory therapies (Translational Andrology and Urology, 2025)
• Clomiphene Citrate in off-Label Post-Cycle Therapy: Mechanisms, Efficacy and Diagnostic Challenges in Endocrine Recovery Following Anabolic Steroid Use (Andrology, 2026)
• Newly Detected Atrial Flutter After Enclomiphene Dose Escalation in a Patient With Prior Mitral Valve Repair and Chronic Immune Thrombocytopenia: A Case Report (Cureus, 2026)
• Leydig stem cells and future therapies for hypogonadism (Current Opinion in Endocrinology, Diabetes, and Obesity, 2020)